$24.9M Tax Refunds Potential and 170% Stock Gain: MariMed (OTC:MRMD) Poised for Growth with 10% Sales Increase – Check It Out Now!

MariMed (OTC:MRMD) Primed for Skyrocketing Stock Gains with Alpha Returns and $24.9M Tax Refunds Potential

$24.9M Tax Refunds & 170% Stock Surge Forecast Amidst Strategic Expansion Plans

MariMed (OTC:MRMD) a multi-state cannabis operator (MSO) is poised for substantial stock gains, according to a recent report by Pablo Zuanic of Zuanic & Associates. The report highlights MariMed’s potential for “alpha” returns meaning gains that exceed the market average, driven by strategic growth plans and the expected rescheduling of cannabis. In the first quarter of 2024 MariMed reported sales of $37.9 million a 10% increase compared to the previous year despite a slight 2.5% decline from the previous quarter. Moreover, according to the report of Markets Insider,, this performance was particularly strong in the wholesale segment which saw a 40% year-over-year growth. Zuanic emphasizes that MariMed’s 10% sales growth even amidst tough retail competition shows the strength of its brand.

MariMed is also set to benefit significantly from tax savings with the expected rescheduling of cannabis. Between 2020 and 2023 the company paid $22.8 million in income taxes. If taxed at a standard 21% rate it would have paid only $8.7 million potentially allowing it to claim $24.9 million in tax refunds. For 2024 MariMed projects gross profits of $74 million and a pre-tax profit of $6.5 million leading to tax savings over $14 million. This along with potential tax refunds could increase the company’s market cap by 170%. The company’s growth strategy includes expanding vertical integration particularly in Illinois and Maryland. New kitchens and cultivation facilities are expected to boost margins by reducing dependence on third-party products. MariMed’s expansion in Illinois, Maryland, and Massachusetts is anticipated to drive significant revenue growth by mid-2025.

READ ALSO: Economic Turmoil: Governor Newsom’s Tax Plan Sparks Debate Over California’s Fiscal Stability

$24.9M Tax Refund Potential and 170% Stock Gain: MariMed (OTC:MRMD) Poised for Growth with 10% Sales Increase – Check It Out Now! (PHOTO: Reason Foundation)

Analyst Projects Higher Figures Amidst Underperformance, Making it a Compelling ‘Overweight’ Investment Opportunity

MariMed’s guidance for the fiscal year includes 5-7% sales growth and 0-2% EBITDA growth but Zuanic projects higher figures of 9% sales growth and 4% EBITDA growth. Additional revenue could come from new recreational sales in Ohio the acquisition of a second store in Maryland and potential tax refunds approval for recreational sales in Massachusetts potentially adding $20 million in annual sales. Despite a 7% decline in its share price over the past 90 days Zuanic believes MariMed’s underperformance is unwarranted. The stock trades at a discount compared to its peers making it a compelling investment. As MariMed continues to expand and show consistent financial performance Zuanic predicts a positive re-rating of the stock closing the valuation gap with its peers. He concludes that MariMed remains a strong investment with the potential for significant growth rating it as “Overweight.” For those interested in the cannabis industry and investment opportunities the 19th Benzinga Cannabis Capital Conference in Chicago on October 8-9 is a must-attend event.

READ ALSO: $11.9M Injected Annually: Shearer’s Foods Expands To Moraine, Ohio, Creating 250 Jobs